JAZZ Pharmaceuticals stopped playing the blues after Phase III data was released indicating it'ssodium oxybate (JZP-6) showed a statistically significant reduction in fibromyalgia pain. Since the drug is already marketed to treat narcolepsy (a… More
This stock has done very well, coming off its lows. With some drugs already having FDA approval, this company is ahead of much of its small competitors. But it is not good enough to be in the top half of your class to maintain this stock price, you… More